Diabetic Peripheral Neuropathy - Pipeline Review, H2 2020

July 2020 | 97 pages | ID: D80FACEEB76EN
Global Markets Direct

Abstracts

Diabetic Peripheral Neuropathy - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Peripheral Neuropathy - Pipeline Review, H2 2020, provides an overview of the Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline landscape.
'Diabetic neuropathy is nerve damage caused by diabetes. The type of neuropathy occurring in the arms, hands, legsand feet is known as diabetic peripheral neuropathy. Symptoms include numbness or tingling in the feet pain ordiscomfort in the feet or legs-including prickly, sharp pain or burning feet, muscle weakness and loss of muscle tonein the feet and lower legs, loss of balance, dry feet and cracked skin. The predisposing factors include diabetes,smoking and kidney diseases. Treatment includes antidepressants, anti-seizure and opioid analgesics.'

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Peripheral Neuropathy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 6, 10 and 1 respectively.
Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Peripheral Neuropathy (Metabolic Disorders).
• The pipeline guide reviews pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Diabetic Peripheral Neuropathy - Overview
Diabetic Peripheral Neuropathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Diabetic Peripheral Neuropathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Diabetic Peripheral Neuropathy - Companies Involved in Therapeutics Development
Achelios Therapeutics Inc
Applied Therapeutics Inc
Bionevia Pharmaceuticals
Bristol-Myers Squibb Co
Calchan Ltd
Celularity Inc
Commence Bio Inc
CSPC Pharmaceutical Group Ltd
Eli Lilly and Co
Exodos Life Sciences Limited Partnership
GNT Pharma Co Ltd
Grunenthal GmbH
Immune Pharmaceuticals Inc
Ion Channel Pharmacology LLC
Jiangsu Aosaikang Pharmaceutical Co Ltd
Korea United Pharm Inc
Medifron DBT Co Ltd
Mitsubishi Tanabe Pharma Corp
Pfizer Inc
Praetego Inc
Reata Pharmaceuticals Inc
Seneca Biopharma Inc
Sonnet BioTherapeutics Holdings Inc
Sphaera Pharma Pte Ltd
Winsantor Inc
YD Life Science Co
Zhejiang Pharmaceutical Co Ltd
Diabetic Peripheral Neuropathy - Drug Profiles
(amitriptyline + ketamine hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diclofenac sodium + triclocarban) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AAD-2004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Diabetic Peripheral Neuropathy - Dormant Projects
Diabetic Peripheral Neuropathy - Discontinued Products
Diabetic Peripheral Neuropathy - Product Development Milestones
Featured News & Press Releases
Aug 16, 2018: Regenacy Pharmaceuticals announces patent issuance for Ricolinostat to treat diabetic peripheral neuropathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Diabetic Peripheral Neuropathy, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by Achelios Therapeutics Inc, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by Applied Therapeutics Inc, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by Bionevia Pharmaceuticals, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by Bristol-Myers Squibb Co, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by Calchan Ltd, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by Celularity Inc, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by Commence Bio Inc, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by CSPC Pharmaceutical Group Ltd, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by Eli Lilly and Co, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by Exodos Life Sciences Limited Partnership, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by GNT Pharma Co Ltd, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by Grunenthal GmbH, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by Ion Channel Pharmacology LLC, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by Korea United Pharm Inc, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by Medifron DBT Co Ltd, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by Pfizer Inc, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by Praetego Inc, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by Reata Pharmaceuticals Inc, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by Seneca Biopharma Inc, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by Sonnet BioTherapeutics Holdings Inc, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by Sphaera Pharma Pte Ltd, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by Winsantor Inc, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by YD Life Science Co, H2 2020
Diabetic Peripheral Neuropathy - Pipeline by Zhejiang Pharmaceutical Co Ltd, H2 2020
Diabetic Peripheral Neuropathy - Dormant Projects, H2 2020
Diabetic Peripheral Neuropathy - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Diabetic Peripheral Neuropathy, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

Achelios Therapeutics Inc
Applied Therapeutics Inc
Bionevia Pharmaceuticals
Bristol-Myers Squibb Co
Calchan Ltd
Celularity Inc
Commence Bio Inc
CSPC Pharmaceutical Group Ltd
Eli Lilly and Co
Exodos Life Sciences Limited Partnership
GNT Pharma Co Ltd
Grunenthal GmbH
Immune Pharmaceuticals Inc
Ion Channel Pharmacology LLC
Jiangsu Aosaikang Pharmaceutical Co Ltd
Korea United Pharm Inc
Medifron DBT Co Ltd
Mitsubishi Tanabe Pharma Corp
Pfizer Inc
Praetego Inc
Reata Pharmaceuticals Inc
Seneca Biopharma Inc
Sonnet BioTherapeutics Holdings Inc
Sphaera Pharma Pte Ltd
Winsantor Inc
YD Life Science Co
Zhejiang Pharmaceutical Co Ltd